-

Dante Omics AI Ushers Genomics Into the AI Age With GPU-Accelerated Proprietary Multiomics Platform

Advanced NVIDIA GPU Integration Transforms Genome and Multiomics Alignment, Variant Calling and Reporting Capabilities

original Dante Omics AI NVIDIA Powered Avanti Software

Dante Omics AI NVIDIA Powered Avanti Software

NEW YORK--(BUSINESS WIRE)--Dante Omics AI, a pioneering force in computational genomics, today announced a groundbreaking upgrade to its proprietary genome and multiomics alignment, variant calling and reporting platform. The enhanced system leverages cutting-edge NVIDIA GPU technology to deliver unprecedented speed and accuracy in genomic analysis, marking a transformative leap forward in bringing genomics fully into the artificial intelligence age.

Dante Omics AI proprietary platform leverages cutting-edge NVIDIA GPU technology to deliver unprecedented speed and accuracy in genomic analysis, marking a transformative leap forward in bringing genomics fully into the artificial intelligence age.

Share

Revolutionary GPU-Accelerated Genomics Pipeline

The upgraded Dante Omics AI platform represents a paradigm shift in how genomic data is processed and analyzed. By harnessing the parallel processing power of NVIDIA GPUs, the Dante Avanti Software dramatically accelerates genome alignment, variant calling and personalized reporting workflows. This technological advancement enables researchers, clinicians, and biopharma to unlock insights from complex genomic datasets with unprecedented efficiency.

"We're witnessing a pivotal moment where artificial intelligence meets genomics at scale," said Andrea Riposati, Dante Omics AI CEO. "Our GPU-accelerated proprietary platform doesn't just make genomic analysis faster – it fundamentally transforms what's possible in personalized medicine, longevity, and population health research."

Key Platform Enhancements

The upgraded Dante Omics AI system delivers several breakthrough capabilities:

Enhanced Multiomics Integration: The platform now seamlessly processes and aligns diverse omics data types – including genomics, transcriptomics, proteomics, and metabolomics – within a unified AI-driven framework.

Scalable AI Architecture: The system's modular design allows for dynamic scaling across multiple GPU configurations, supporting everything from individual cases to large-scale population studies.

Precision Medicine Applications: Enhanced accuracy in variant detection and annotation supports more precise therapeutic targeting and personalized treatment strategies.

Transforming Genomics Research and Clinical Practice

The platform's multiomics capabilities are particularly significant for complex disease research, where understanding the interplay between different biological layers is crucial for developing effective treatments. By integrating genomic, transcriptomic, and proteomic data within a single AI-powered framework, researchers can identify novel therapeutic targets and biomarkers with greater precision.

For more information, visit DanteOmics.com.

About Dante Omics AI

Dante Omics AI is a leading provider of AI-powered genomics solutions, dedicated to accelerating discovery and improving patient outcomes through advanced computational biology tools. The company's innovative platform combines cutting-edge artificial intelligence with high-performance computing to deliver transformative genomic analysis capabilities for research institutions, clinical laboratories, and biotechnology companies worldwide.

Contacts

Media:
Laura Rossi
+39 0862 191 0671
media@danteomics.com

Industry:

Dante Omics

Details
Headquarters: New York, USA
CEO: Andrea Riposati
Employees: 42
Organization: PRI
Release Versions
EnglishItalian

Contacts

Media:
Laura Rossi
+39 0862 191 0671
media@danteomics.com

Social Media Profiles
Dante Labs on LinkedIn
Dante Labs YouTube Channel
More News From Dante Omics

More Than 100 Scientific Papers Leveraged the Dante Labs Technology for Research on Transcriptomics, CRISPR Gene Editing, Ancient DNA samples, Rare Diseases and Oncology

NEW YORK--(BUSINESS WIRE)--Dante Labs enabled more than 100 global scientific studies on rare diseases, transcriptomics, CRISPR gene editing ancient DNA samples and oncology. Dante Labs also published its own papers on peer reviewed journals, including Gene and Nature Communications. Scientists and academic researchers from the US, Italy, Pakistan, Malta and more European countries keep choosing Dante Labs to sequence samples for important studies. Topics include rare diseases, phasing, oncolog...

No one listened. Then a Dante Labs Whole Genome Report Gave a Single Mother's Two Children a Name for Their Disease and Access to the Specialists They Needed

NEW YORK--(BUSINESS WIRE)--For years, Susan watched her two children collapse without warning. Episodes of sudden, full-body muscle weakness that came and went — sometimes lasting minutes, sometimes hours. Between episodes, they looked like any other healthy kids. And that was the problem. Susan, a single mother in a small town in New Zealand, took her children to doctor after doctor. Blood panels came back normal. She was told the symptoms were stress-related. No referrals. No follow-up. No an...

Trieste, L'Aquila, Rome: the Italian genomics triangle assembles the new diploid RPE-1 genome, the missing piece for CRISPR, immediately published in California and on Nature magazine – with Dante Labs, Area Science Park, and La Sapienza University

ROME--(BUSINESS WIRE)--A few weeks ago, the USCS Genome Browser at the University of California, Santa Cruz, the bible of reference genomics, published a new and very important reference genome, Diploid RPE-1, key to the study of centromeres, thanks to the work of the Area Science Park in Trieste, the Giunta Lab at Sapienza University, Dante Labs, and the University of L'Aquila. These innovative Italian institutions have formed an international alliance with Rockefeller University in New York a...
Back to Newsroom